$6.200
-0.295 (-4.76%)收盤時
- High
- 9.680
- Open
- 7.150
- VWAP
- 7.31
- Vol
- 4.14M
- Mkt Cap
- —
- Low
- 6.050
- Amount
- 30.23M
- EV/EBITDA, TTM
- 0.00
Aptorum Group Limited is a United Kingdom-based clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The Company's pipeline is also enriched through the co-development of PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research.
AI analysis of NIKI (NIKI)
sellNiki Biosolutions, Inc. is not a good buy right now due to significant declines in stock price and negative financial indicators. The current price is $6.20, down 91.14% year-to-date, and the RSI is at a very low 10.191, indicating oversold conditions. The forward P/E ratio is 0, suggesting no earnings growth is expected in the near future, which is a major concern.
估值指標
事件時間軸
NIKI FAQ — answered by Alphio AI
Niki Biosolutions, Inc. is not a good buy right now due to significant declines in stock price and negative financial indicators. The current price is $6.20, down 91.14% year-to-date, and the RSI is at a very low 10.191, indicating oversold conditions. The forward P/E ratio is 0, suggesting no earnings growth is expected in the near future, which is a major concern.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。